PRTODAY / NewswireToday Free press release distribution service network

Written by / Agency / Source: Report Buyer Ltd

Check Ads Availability|e-mail Article


Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!

Parkinson’s Disease Therapeutics to Exceed $4.6 billion Revenue by 2012 Says New Report - Report Buyer has added a new report showing that the revenues of Parkinson’s Disease (PD) therapeutics across the major markets (US, Japan, France, Germany, Italy, Spain and the UK) totalled over $2.2 billion in 2006
Parkinson’s Disease Therapeutics to Exceed $4.6 billion Revenue by 2012 Says New Report

 

NewswireToday - /newswire/ - London, United Kingdom, 2008/04/17 - Report Buyer has added a new report showing that the revenues of Parkinson’s Disease (PD) therapeutics across the major markets (US, Japan, France, Germany, Italy, Spain and the UK) totalled over $2.2 billion in 2006.

   
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma/BioTech/Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Report Buyer, the online destination for business intelligence for major industry sectors, has added a new report showing that the revenues of Parkinson’s Disease (PD) therapeutics across the major markets (US, Japan, France, Germany, Italy, Spain and the UK) totalled over $2.2bn in 2006, with revenues expected to exceed $4.6bn by 2012. In 2006, the global sales of PD therapeutics were $3.1bn up by 11% from $2.5bn in 2005.

“Parkinson's Disease Market analysis and forecasts”, reports that PD is the second most common neurological disorder, affecting approximately 4.1m people worldwide. As the prevalence rate of PD is set to rise significantly in the coming years, clinical interventions will play a major role in combating the wide spectrum of unmet needs associated with the disease.

The report analysis PD sales over the next 15 years and delivers the percentage market growth. The projected revenue growth will be driven largely by reformulations that will decrease the burden of polypharmacy in patients receiving PD pharmacotherapy. The leading therapeutics expected to change the PD market dynamics will include, GlaxoSmithKline's (GSK's) Requip Once-daily ER awaiting approval, UCB-Schwarz's Neupro, Teva and Lundbeck's Azilect.

Other key compounds predicted for success include Kyowa Hakko's Istradefylline, Merck-Serono/Newron's Safinamide. The new wave of Gene/cell Therapy compounds that have revealed positive initial clinical data, thus Neurotrophic growth factors (NGF), either to be injected directly into the brain are also tipped for potential market success. Ceregene's Neuturine, Neurologix' GAD (glutamic acid decarboxylase) amongst other similar drugs, will add to the present PD therapeutics that will expand revenue growth in the long-term.

“Parkinson's Disease Market analysis and forecasts” is available from Report Buyer. For more information, see website.

Report Buyer product ID: VIS00056

About Report Buyer
Report Buyer is a UK-based independent online store supplying business information. The website now carries over 44,000 business information products, including market reports, studies, books and events. Subscribers receive a free monthly newsletter and email alerts on new titles in their areas of interest. A regularly updated blog provides information on the latest market trends.

 
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma/BioTech/Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Written by / Agency / Source: Report Buyer Ltd

 
 

Availability: All Regions (Including Int'l)

 

Traffic Booster: [/] Quick Newswire Today Visibility Checker

 

Distribution / Indexing: [+]

 
 
# # #
 

 
  Your Banner Ad showing on ALL
Pharma/BioTech/Nutrition articles,
CATCH Visitors via Your Competitors Announcements!


Parkinson’s Disease Therapeutics to Exceed $4.6 billion Revenue by 2012 Says New Report

Company website links NOT available to basic submissions
It is OK to republish and/or LINK any newswire for any legitimate media purpose as long as you name Newswire Today and LINK as the source.
 
  Is this your article?
Activate ALL web links and social stream by Upgrading to Press Release PREMIUM Plan Now!

|
Publisher Contact: Jonna Dagliden 
+44 (0) 20 7060 7474 press[.]reportbuyer.com
 
Newswire Today - PRZOOM / PRTODAY disclaims any content contained in this article. If you need/wish to contact the company who published the current release, you will need to contact them - NOT us. Issuers of articles are solely responsible for the accuracy of their content. Our complete disclaimer appears here.
IMPORTANT INFORMATION: Issuance, publication or distribution of this press release in certain jurisdictions could be subject to restrictions. The recipient of this press release is responsible for using this press release and the information herein in accordance with the applicable rules and regulations in the particular jurisdiction. This press release does not constitute an offer or an offering to acquire or subscribe for any Report Buyer Ltd securities in any jurisdiction including any other companies listed or named in this release.

Pharma/BioTech/Nutrition via RSSAdd NewswireToday - PRZOOM Headline News to FeedBurner
Find who RetweetFollow @NewswireTODAY



Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!


Read Latest Articles From Report Buyer Ltd / Company Profile


Read Pharma/BioTech/Nutrition Most Recent Related Newswires:

Frost & Sullivan Commends Nemaura for Developing Superior Transdermal Drug Delivery Technology Platforms, the Memspatch and Micropatch
Greenphire Sponsors Second Annual Clinical Trial Agreements, Investigator Payments and Fair Market Value Meeting
Genentech’s Gazyva Helped People with Previously Untreated Follicular Lymphoma Live Significantly Longer
BD Announces Adoption of Windows 10 ‘Internet of Things’ for the Pyxis™ ES System
Greenphire Named to Deloitte 2016 Technology Fast 500™
Genentech Showcases New Clinical Data Across a Variety of Blood Diseases at American Society of Hematology 2016 Annual Meeting
BD Collaborates with JDRF to Focus on Extended Wear Innovations for Insulin Infusion Delivery
BD Launches First Syringe Designed for Use with Humulin® R U-500 Insulin
MDxHealth Announces Unique CPT Code Awarded for ConfirmMDx from the American Medical Association
BD MAX™ Vaginal Panel Receives FDA Market Authorization to Detect Most Common Causes of Vaginal Infections
Greenphire Receives EU-US Privacy Shield Certification
The 2016 Georges Mathé Prize Recognizes Research on the Immunological Determinants of the Response to Breast Cancer Treatment
MDxHealth Announces Agreement with HIFU CLINIC Prostate Cancer Center for Distribution of SelectMDx in Poland
First Patient in Malaysia Receives TheraSphere™ Radioembolisation Therapy
FDA Approves Genentech’s Lucentis® (Ranibizumab Injection) Prefilled Syringe

Boost Your Social Network
& Crowdfunding Campaigns


LIFETIME SOCIAL MEDIA WALL
NewswireToday Celebrates 10 Years in Business


PREMIUM Members


Visit  La Bella Bakery Artisan Bakery Arizona

Visit  Triggr & Bloom





 
  ©2016 Newswire Today — Limelon Advertising, Co.
Home | About | Advertise/Pricing | Contact | Investors | Privacy/TOS | Sitemap | FRANCAIS
newswire, PR free press releases distribution service magazines engine news alert newsroom press room breaking news public relations articles company news alerts newswiredistribution ezine bizentrepreneur biznewstoday digital business report market search pr firms agencies reports distri-bution today investor relation successful internet entrepreneurs newswire distribution prtoday.com freenewswiredistribution asianewstoday bizwiretoday USA pr UK today - NOT affiliated with PRNewswire as we declined their partnership offer in 2013
 
PRTODAY & NewswireTODAY are NOT affiliated with USA TODAY (usatoday.com)